Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases
Inflammasome Therapeutics is entitled to receive up to $160 million in milestone and gated development payments as well as tiered royalties and other milestones due on commercialization.
Merck’s Pifeltro and Delstrigo get US FDA approval for use in appropriate virologically suppressed adults living with HIV-1
USAFDA has given approvals for Merck’s Pifeltro and Delstrigo for certain HIV-1 patients, based on fFindings from the Phase 3 DRIVE-SHIFT Trial, Merck said on Friday in a press release.
LOS ANGELES–(BUSINESS WIRE)–#biomarkers–In promoting Andrew Aijian to Partner, DeciBio Consulting announces its first addition to the Partnership since its formation.
STRASBOURG, France–(BUSINESS WIRE)–#Defymed—Medical technology company Defymed, specialized in the design and development of innovative medical devices for the delivery
Kraig Biocraft Laboratories have named a new member to its expanded Board of Directors, who will be joining the company as an independent director.
Cerevel Therapeutics to Present Results from a Phase 2 Study of Tavapadon in Patients with Early-stage Parkinson’s Disease
Cerevel Therapeutics is expecting to presented data from studying Tavapadon in patients with early-stage Parkinson’s Disease, at the 2019 International
San Francisco based clinical-stage biotech company Five Prime Therapeutics has named the new interim Chief Executive Officer, William Ringo, who will start immediately, to replace Aron Knickerbocker, who has resigned to look for new opportunities.
Dicerna has announced Retirement of Board of Director Veteran Dennis Langer, and to his place has named Patrick Gray.
Bristol-Myers Squibb show breadth of oncology development program and focus on improving overall survival across multiple cancers
Overall survival data from CheckMate -227 Part 1 evaluating Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) in advanced non-small cell lung cancer featured in ESMO Presidential Symposium
WASHINGTON–(BUSINESS WIRE)–#Medicare–Today, Citizens Against Government Waste (CAGW) released the following comments regarding House Speaker Nancy Pelosi’s (D-Calif.) partisan drug pricing